Through subcutaneous tumor and peritoneal implantation models in nude mice, we found that POLQ inhibitors in combination with sulfasalazine synergistically exhibited anti-tumor effects, holding significant potential for direct translational applications in cancer therapy. The gene discussed is POLQ; the disease is neoplasm.